13N-ammonia

DRUG4 trials

Sponsors

National Institute of Neurological Disorders and Stroke (NINDS), Sanofi, Washington University School of Medicine

Conditions

Autonomic FailureAutonomic Nervous System DiseasesCoronary Artery DiseaseMicrovascular Coronary Artery DiseaseMultiple System AtrophyParkinson DiseaseParkinson's DiseasePure Autonomic Failure

Early Phase 1

Myocardial Perfusion Imaging Galmydar Rest/Stress

CompletedNCT05625490

Washington University School of MedicineCoronary Artery Disease

Start: 2022-11-11End: 2025-12-19Updated: 2026-01-07

Phase 2

A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI

TerminatedNCT03236311

SanofiMicrovascular Coronary Artery Disease

Start: 2017-10-12End: 2018-07-23Updated: 2022-03-24

Unknown Phase

Biomarkers of Risk of Parkinson Disease

CompletedNCT00775853

National Institute of Neurological Disorders and Stroke (NINDS)Autonomic Nervous System Diseases, Parkinson Disease, Pure Autonomic Failure

Start: 2009-05-27End: 2023-01-11Updated: 2025-09-19

Clinical Laboratory Evaluation of Chronic Autonomic Failure

Active, not recruitingNCT03648905

National Institute of Neurological Disorders and Stroke (NINDS)Autonomic Failure, Multiple System Atrophy, Parkinson's Disease

Start: 2018-09-06End: 2029-12-31Updated: 2026-04-01

Related Papers

Cardiac noradrenergic deficiency revealed by 18F-dopamine positron emission tomography identifies preclinical central Lewy body diseases.

2024-01-0226 citations